Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • rehdvm2004 rehdvm2004 Nov 23, 2012 10:28 AM Flag

    FaceTheFacts INSM Longs - Update CF/Pa Study

    The CF/Pa clinical trial in Europe has been updated to "Active, Not Recruiting" which verifies the probability that the 300 patient enrollment milestone has been met. The other 61 clinical sites (other than Brompton and the 3 Canadian sites) have still not been added. I would personally like to see both peices of information. If you got to the Chiltren (spelling?) website, or the previous inhalational antibiotic sites that Chiltren mediated for TOBI, Cayston, et al, you can back trace which sites are which. But that is a pain. If there is an interim data report from Chiltren and there is log reduction plus improved FEV1, there might be a real pop before or after the New Year.

    If we get an update on NTM, the announcement may be very significant.

    We shall see in the coming weeks.

    Sentiment: Hold

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The CF/Pa clinical trial in Europe has been updated to "Active, Not Recruiting" which verifies the probability that the 300 patient enrollment milestone has been met. The other 61 clinical sites (other than Brompton and the 3 Canadian sites) have still not been added. I would personally like to see both peices of information. If you got to the Chiltren (spelling?) website, or the previous inhalational antibiotic sites that Chiltren mediated for TOBI, Cayston, et al, you can back trace which sites are which. But that is a pain. If there is an interim data report from Chiltren and there is log reduction plus improved FEV1, there might be a real pop before or after the New Year.

      If we get an update on NTM, the announcement may be very significant.

      We shall see in the coming weeks.

    • As Bo and pianoman have already pointed out, "amazin, simply amazin and Probability"???

      You want to come across as you are an authority of information/knowledge/experience... Yet you have been exposed over and over again as simply trying too hard (at best) and intimating INSM management does not know as much as you do concerning their products (pretentiousness on your part). Regarding the " other 61 sites", do they HAVE to be listed on U.S. Clinical Trials website (individually or in groups)? Have you checked the EU site to see there are clues there (you are the master of DD, after all)?

      At least I post with only one ID, why don't you answer the questions posed to you? When one does NOT respond to questions, they have zero credibility and YOU have passed the zone of relevance.

    • "Probability"??? Dude, what are you smoking? Maybe just too much turkey... It's been officially PR'd, man!
      painoman

      Sentiment: Strong Buy

      • 1 Reply to jsblvbjb
      • Just because something sounds "cool" doesn't mean it's necessarily a winner. Take Insmed (Nasdaq: INSM ) for example, which debuted on the Nasdaq in June 2000 and has eroded 95% of shareholders' investment since then. Over the trailing 10-year period, Insmed has burned through about $216 million in cash and still doesn't have an drug approved by the Food and Drug Administration to show for it.

        Insmed currently has multiple clinical trials being run for its inhalable liposomal amikacin, known as Arikace, which is being targeted at serious lung infections, including cystic fibrosis. Testing of the drug in mid-stage trials suggests Arikace was well-tolerated and more effective than the placebo; however, a clinical trial halt (which is over now) by the FDA in early August of last year over safety concerns in tested animals reminded investors just how fragile and uncertain Arikace's chances of approval still are. Even with ample cash in hand, I wouldn't put yet another secondary offering over on Insmed, nor would I assume that an approval would put Insmed in the green considering all it's invested in Arikace's development, and the costs of acquiring the experimental treatment by purchasing Transave. Conceptually, the treatment sounds fantastic, but I'm not sold on Insmed at $8.

 
INSM
13.22+0.32(+2.48%)Aug 26 4:00 PMEDT